Continuum P 3-Year DOI (Canada)

Manufacturer: Merck Animal Health

Parvovirus Vaccine

Modified Live Virus

Product Description: Continuum™ P Is A Modified Live Virus Vaccine Containing An Attenuated Strain Of Canine Parvovirus (cpv). continuum™ P Is Presented In A Desiccated Form With Sterile Diluent Provided For Reconstitution. The Parvovirus Component Is Patented^* cpv Strain 154^® Which Is An Attenuated Parvovirus Strain Of Canine Origin. continuum™ P Is Produced With A High Titered Cpv Component Which Is Immunogenic.

indications

For the vaccination of healthy dogs as an aid in the prevention of disease caused by canine parvovirus for up to 3 years following initial and booster vaccinations.

Safety Data

Extensive safety testing has demonstrated that CPV STRAIN 154^® is safe when given to puppies as young as 4 weeks of age.

Efficacy Data

Seronegative pups, vaccinated at 7 and 11 weeks of age were held in strict isolation for 3 years (36 months) following the last vaccination and then challenged with CPV. Serum antibody titers for CPV were measured throughout the isolation period (Table 1). The geometric mean antibody titer (GMT) remained at high levels throughout the isolation period.

Table 1. Geometric mean titers (GMT) in dogs following second vaccination with CPV.

Virus Fraction (Assay)	Pre- vac	Months After Vaccination
		1	3	6	9	12	21	24	30	33	36
CPV (HI)	<10	567	680	1444	395	640	350	257	192	151	237

At 36 months post vaccination, the GMT for CPV was 1:237. Thirty-six months following vaccination, the dogs were challenged with CPV (CPV-2b field isolate, oral/nasal challenge). For each virus challenge, 6 age-matched, nonvaccinated control pups were also challenged.

Cpv Challenge

Following CPV-2b challenge, all 6 control dogs exhibited lymphopenia and severe clinical signs of CPV (including depression, diarrhea, dehydration, anorexia, vomiting, and pyrexia) lasting between 3-11 days duration. Two (33%) of the 6 control dogs died following challenge (Table 2). Fecal samples were evaluated for virus isolation using standard hemagglutination (HA) methods. Dogs with viral hemagglutinins at a level of ≥ 1:64 in a 1:5 dilution of feces were considered to be infected and shedding virulent CPV virus. All of the control dogs excreted virulent CPV virus in their feces; whereas none of the vaccinates excreted virus. Eight of the 22 vaccinated dogs had infrequent clinical signs that were of short duration (≤ 2 days) and noncontiguous events. Although clinical signs resulting from CPV-2b infections characteristically appear between 4-5 days post challenge, diarrhea and vomiting were reported as early as 1 day post challenge in some of the vaccinated dogs. Clinical signs required for CPV infection were prevented in 100% of the vaccinated dogs.

Table 2. Cpv-2b Challenge.

treatment	Dogs	Positive Virus Isolation	Lymphopenia ≥ 50% baseline Value	Clinical Signs (# Days Sick)*	death
CONTINUUM™ P	22	0	0	8 (≤2)	0
Control	6	6	6	6 (3-11)	2

* Depression, diarrhea, dehydration, anorexia, vomiting, pyrexia

The prevented fraction of CONTINUUM™ P was evaluated by challenge (Table 3). The prevented fraction is the proportion of infection prevented by the vaccine relative to the infection rate in nonvaccinated dogs. The prevented fraction was 100% for CPV challenge.

Table 3. Prevented Fraction.

fraction	Continuum™ P
	Prevented Fraction	95% Confidence Interval
CPV	100%	85%, 100%

The results of this study demonstrate that the modified-live CPV in CONTINUUM™ P provides protection against virulent CPV challenge in 7-weeks-of-age or older dogs for a minimum of 3 years following second vaccination.

Directions For Use

Aseptically reconstitute the desiccated vaccine with the sterile diluent provided and administer 1 mL by the subcutaneous route. Initial vaccination of healthy dogs may be given as early as 6 weeks of age, with booster injections administered every 3-4 weeks until 12 weeks of age. Dogs over 12 weeks of age should initially receive 2 doses 3-4 weeks apart. Revaccinate every three years with a single dose thereafter.

Precautions

1. Recommended storage temperature 2-7°C (35-45°F).

2. Shake well before use.

3. Use contents promptly once reconstituted.

4. Non-chemically sterilized needles and syringes should be used for administration of vaccine.

5. Avoid vaccinating pregnant bitches.

6. Administration of epinephrine may be indicated in the event of an anaphylactic reaction.

7. Contains gentamicin as a preservative.

8. Burn this container and all unused contents.

9. Only healthy animals should be vaccinated. Animals incubating any disease or animals stressed due to shipping, malnutrition, or parasitism may not achieve or maintain an adequate immune response.

10. This product is not hazardous when used according to directions supplied. A material safety data sheet (MSDS) is available upon request. This and any other consumer information can be obtained by calling toll free Intervet Canada Corp. Customer Service at 1-866-683-7838.

Supplied

Cartons of 25 1-dose/1-mL desiccated vaccine vials and 25 1-mL sterile diluent vials. Packaged in recyclable plastic containers.

Sales Product Code No.

026778

For Veterinary Use Only

U.s. Veterinary License No. 165a

Intervet Inc., Millsboro, De 19966

For technical enquiries, call toll free 1 888 306-0069.

™Trademark of Intervet International B.V., used under license by Intervet Canada Corp.

*U.S. Patent Nos. 4,810,494 and 5,316,764

Rev. 915501

AL 408

Nac No.

12081923